Koichiro Furuta

Hamada, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Underwater Endoscopic Submucosal Dissection under General Anesthesia for Superficial Esophageal Carcinoma.

Underwater Endoscopic Submucosal Dissection under General Anesthesia for Superficial Esophageal Carcinoma.

Journal: Endoscopy international open

Published: April 18, 2026

Incomplete Intestinal Metaplasia in Pyloric Gland Mucosa of Helicobacter pylori-Naïve Stomachs: A Prospective Multicenter Histopathologic Study.

Incomplete Intestinal Metaplasia in Pyloric Gland Mucosa of Helicobacter pylori-Naïve Stomachs: A Prospective Multicenter Histopathologic Study.

Journal: Pathology international

Published: March 18, 2026

Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.

Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.

Journal: Journal of gastroenterology and hepatology

Published: December 15, 2024

Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.

Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.

Journal: BMJ open

Published: November 24, 2024

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: March 22, 2023

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

Journal: Investigational new drugs

Published: January 14, 2023

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Journal: Investigational new drugs

Published: August 12, 2022

Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.

Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 02, 2022

Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.

Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.

Journal: Hepatology (Baltimore, Md.)

Published: May 25, 2022

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.

Journal: Cancers

Published: May 22, 2022

Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.

Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.

Journal: Journal of medical virology

Published: May 22, 2022

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: March 24, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026